Dr Aaron Lisberg from the University of California, Los Angeles, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. 

CME information and select publications here.

Dr Kathleen N Moore from OU Health Stephenson Cancer Center in Oklahoma City, Oklahoma, and Dr Matthew A Powell from the Washington University School of Medicine in St Louis, Missouri, discuss recent updates on available and novel treatment strategies for endometrial cancer. 

CME information and select publications here.

Prof Patrick Neven from University Hospitals Leuven in Leuven, Belgium, discusses recent updates on available and novel treatment strategies with oral SERDs for ER-positive metastatic breast cancer.   

CME information and select publications here.

Dr John Strickler from Duke University in Durham, North Carolina, discusses the measurement of molecular residual disease and its current and potential role in colorectal cancer risk assessment, surveillance and treatment decision-making. 

CME information and select publications here.

Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of breast cancer. 

CME information and select publications here.

Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, discusses recent datasets and their implications for the current and future management of acute myeloid leukemia.  

CME information and select publications here.

Dr Aditya Bardia and Dr Adam M Brufsky discuss published and emerging datasets investigating the incorporation of antibody-drug conjugates into the treatment of metastatic breast cancer.

CME information and select publications here.

Dr Aaron Lisberg from the University of California, Los Angeles discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. 

CME information and select publications here.

Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, and Dr Brad S Kahl from Siteman Cancer Center in St Louis, Missouri, review recent datasets and their significance for the management of various forms of non-Hodgkin lymphoma. 

CME information and select publications here.

Dr Laura Huppert from the University of California, San Francisco, discusses approved and investigational antibody-drug conjugates in the current and future management of HR-positive and triple-negative metastatic breast cancer. 

CME information and select publications here.